Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle...

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Non-muscle invasive bladder cancer (NMIBC) accounts for a significant portion of bladder cancer diagnoses.
• Transurethral resection of bladder tumor (TURBT) is the primary treatment for NMIBC.
• Recurrence after TURBT is common, necessitating identification of risk factors for improved patient outcomes.

Purpose of the Study:

• To investigate risk factors for recurrence in NMIBC patients post-TURBT.
• To establish a basis for clinical strategies aimed at preventing NMIBC recurrence.

Main Methods:

• Retrospective study of 592 NMIBC patients undergoing TURBT from 2012-2020.
• Patients categorized into relapse (within 2 years) and relapse-free groups.
• Analysis of clinical and pathological factors, including age, smoking, comorbidities, tumor characteristics, and intravesical treatments (pirarubicin, BCG, mitomycin).

Main Results:

• The 2-year recurrence rate was 17.06%.
• Multivariate analysis identified high pathology grading (OR=0.403, p=0.0241), pirarubicin treatment (OR=1.961, p=0.0125), and BCG treatment (OR=6.201, p=0.0190) as independent risk factors for recurrence.
• Univariate analysis also suggested T1 stage and mitomycin treatment as potential risk factors.

Conclusions:

• High pathology grading, pirarubicin, and BCG treatment are significant independent risk factors for NMIBC recurrence post-TURBT.
• Findings underscore the importance of vigilant postoperative surveillance and personalized treatment approaches.
• Further research is recommended to validate these risk factors, particularly the impact of mitomycin and BCG, due to sample size limitations.